[go: up one dir, main page]

GB201008123D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
GB201008123D0
GB201008123D0 GBGB1008123.0A GB201008123A GB201008123D0 GB 201008123 D0 GB201008123 D0 GB 201008123D0 GB 201008123 A GB201008123 A GB 201008123A GB 201008123 D0 GB201008123 D0 GB 201008123D0
Authority
GB
United Kingdom
Prior art keywords
novel compounds
infection
treatment
present
hcv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1008123.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biotica Technology Ltd
Original Assignee
Biotica Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotica Technology Ltd filed Critical Biotica Technology Ltd
Priority to GBGB1008123.0A priority Critical patent/GB201008123D0/en
Publication of GB201008123D0 publication Critical patent/GB201008123D0/en
Priority to PCT/GB2011/050928 priority patent/WO2011144924A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to macrocyclic sanglifehrin analogues, that are useful as cyclophilin inhibitors, e.g. in the treatment of viral infection especially infection by RNA viruses, such as Hepatitis C virus (HCV) and HIV, and muscular dystrophy. The present invention also provides methods for their use in medicine, in particular for the treatment of HCV infection.
GBGB1008123.0A 2010-05-17 2010-05-17 Novel compounds Ceased GB201008123D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1008123.0A GB201008123D0 (en) 2010-05-17 2010-05-17 Novel compounds
PCT/GB2011/050928 WO2011144924A1 (en) 2010-05-17 2011-05-16 Amine or amid analogues of sanglifehrin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1008123.0A GB201008123D0 (en) 2010-05-17 2010-05-17 Novel compounds

Publications (1)

Publication Number Publication Date
GB201008123D0 true GB201008123D0 (en) 2010-06-30

Family

ID=42334812

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1008123.0A Ceased GB201008123D0 (en) 2010-05-17 2010-05-17 Novel compounds

Country Status (2)

Country Link
GB (1) GB201008123D0 (en)
WO (1) WO2011144924A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104703991B (en) * 2012-06-08 2018-03-23 吉利德科学公司 Macrocyclic Inhibitors of Flaviviridae Viruses
PL2859009T3 (en) 2012-06-08 2018-03-30 Gilead Sciences, Inc. Macrocyclic inhibitors of flaviviridae viruses
AR091279A1 (en) 2012-06-08 2015-01-21 Gilead Sciences Inc MACROCICLIC INHIBITORS OF VIRUS FLAVIVIRIDAE
CN110062626A (en) 2016-11-18 2019-07-26 纽维制药有限公司 Use of sanglifehrin macrocyclic analogs as anticancer compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124453A (en) 1995-07-04 2000-09-26 Novartis Ag Macrolides
AR006514A1 (en) 1995-07-04 1999-09-08 Sandoz Ag A MACROLID, ITS USES, A PROCESS TO PRODUCE IT, A BIOLOGICALLY PURE ISOLATE CAPABLE OF PRODUCING IT, AND A PHARMACEUTICAL COMPOSITION THAT IT INCLUDES
AR054778A1 (en) 2005-06-17 2007-07-18 Novartis Ag USE OF SANGLIFERINA IN HCV
EP2124992A2 (en) 2007-01-04 2009-12-02 Debiopharm S.A. Non-immunosuppressive cyclosporin for treatment of ullrich congenital muscular dystrophy
ES2541853T3 (en) * 2010-02-09 2015-07-27 Neurovive Pharmaceutical Ab Sangliferin based compounds

Also Published As

Publication number Publication date
WO2011144924A1 (en) 2011-11-24

Similar Documents

Publication Publication Date Title
TN2012000264A1 (en) Hepatitis c virus inhibitors
TN2012000214A1 (en) Hepatitis c virus inhibitors
MX2011008045A (en) Hepatitis c virus inhibitors.
MY152971A (en) Hepatitis c virus inhibitors
MX2013001237A (en) Hepatitis c virus inhibitors.
MY202109A (en) Viral replication inhibitors
MX2010008749A (en) Hepatitis c virus inhibitors.
EA201390538A1 (en) ANTI-VIRUS COMPOUNDS
PH12013501543A1 (en) Hepatitis c virus inhibitors
MX2010008531A (en) Conformationally restricted biphenyl derivatives for use as hepatitis c virus inhibitors.
EA201791776A1 (en) SUBSTITUTED CYCLOPHANES FOR USE WHEN TREATING HCV INFECTION
PH12014500557A1 (en) Methods for treating hcv
MX2013006475A (en) Macrocyclic inhibitors of flaviviridae viruses.
IN2014MN01548A (en)
PH12013502177A1 (en) Hepatitis c virus inhibitors
PH12014500385A1 (en) Benzofuran compounds for the treatment of hepatitis c virus infections
GB201008123D0 (en) Novel compounds
PH12014500283A1 (en) Hcv immunotherapy
UA113048C2 (en) ANTI-VIRUS COMPOUNDS
TN2013000453A1 (en) Hepatitis c virus inhibitors
TN2013000335A1 (en) Hepatitis c virus inhibitors
PH12019501907B1 (en) Viral replication inhibitors
EA201990314A1 (en) NEW VIRAL REPLICATION INHIBITORS
UA108671C2 (en) HEPATITIS VIRUS INHIBITORS C.
CY1114249T1 (en) INHIBITIONS OF VIRUS USITIS C.

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)